Introduction
The low density lipoprotein receptor-related protein / a2-macroglobulin receptor (LRP/a2MR)1 is a large cell surface glycoprotein that binds several unrelated ligands including a2-macro-Receivedfor publication 18 December 1992 and in revisedform 15 March 1993. globulin-proteinase (a2M*) (1, 2) , apolipoprotein E-enriched B-migrating very low density lipoprotein (I3VLDL) (3) (4) (5) (6) , lipoprotein lipase (7) , urokinase/plasminogen activator inhibitor type-1 complex (8), Pseudomonas exotoxin A (9), and a 39-kD copurifying protein, also termed receptor-associated protein (RAP) (1, (9) (10) (11) (12) . LRP/a2MR is synthesized as a single polypeptide chain of approximately 600 kD and is cleaved in a trans-Golgi compartment into two subunits of 515 and 85 kD, which remain associated with one another via trafficking to the cell surface (13) . Metabolic pulse-chase labeling studies have demonstrated that newly synthesized 39-kD protein associates with LRP/a2MR intracellularly. Surface labeling experiments have shown that the 39-kD protein is present on the cell surface as a complex with the 515 and 85 kD subunits of LRP/ a2MR (14) . The 39-kD protein is a potent inhibitor of all known ligand interactions with the receptor, as shown by ligand blotting and by cellular uptake experiments in cultured cells expressing LRP/ a2MR (1, 8, 9, 15) . In addition to copurifying with LRP/a2MR, the 39-kD protein copurifies with glycoprotein 330 (gp330) (12) , a third member ofthe LDL receptor gene family (16, 17) that has been identified as a receptor site for the serum protein plasminogen (18) . The human 39-kD protein is the homolog of a 44-kD rat protein identified in kidney as a component ofthe gp330/44-kD Heymann nephritis antigenic complex (14, 19) . The 39-kD protein is also the homolog of a mouse protein termed heparin-binding protein 44 (20) . The physiological role ofthe 39-kD protein is unclear. However, the above findings have led to the proposal that in vivo the 39-kD protein may function as a regulator of LRP/ a2MR activity. The 39-kD protein may function in a similar role with regard to gp330.
We recently demonstrated from chemical cross-linking and immunoprecipitation experiments that LRP/a2MR can function as a clearance receptor for tissue-type plasminogen activator (t-PA) in rat hepatic MHICI cells (21) and human hepatoma HepG2 cells (22) and that the 39-kD protein inhibits t-PA binding to these cells. t-PA is an endogenous plasma serine protease that converts the zymogen plasminogen to the protease plasmin. The resultant activated plasmin can proteolytically degrade the fibrin network associated with thrombi. t-PA has been used clinically to dissolve thrombi within coronary arteries associated with acute myocardial infarction (23) . A major drawback to the clinical use oft-PA is its rapid plasma clearance, ranging from a t, /2 of 1-4 min in rodents (24-29) to [5] [6] [7] [8] [9] [10] min in humans (30, 31) . In vivo clearance studies have shown that the liver is the primary organ responsible for the rapid uptake of t-PA from the circulation (24) (25) (26) (27) (28) (29) (30) (31) . Studies 1. Abbreviations used in this paper: gp330, glycoprotein 330; GST, glutathione S-transferase; LRP/a2MR, low density lipoprotein receptor-related protein/a2-macroglobulin receptor; RAP, receptor-associated protein; t-PA, tissue-type plasminogen activator; a2M*, pro-with whole animals and with isolated liver cell preparations suggest that both oligosaccharide-dependent, mediated by mannose receptors on liver endothelial cells, and oligosaccharideindependent mechanisms, mediated via parenchymal cells, contribute to the clearance of t-PA from the circulation (32) . Two distinct parenchymal cell clearance mechanisms appear to exist, based on whether or not t-PA forms a complex with plasminogen activator inhibitor type 1 (PAI-1 ). The relative contribution of these two systems to t-PA clearance may vary according to the physiological situation. We previously reported that free t-PA binds to LRP/a2MR on MH1C1 cells (21) . Orth et al. (33) demonstrated, via ligand blotting, the binding oft-PA/PAI-l complexes to isolated LRP/a2MR. Recently we demonstrated that t-PA/PAI-l complexes bind to LRP/a2MR on HepG2 cells (22) . The 39-kD protein inhibits the binding of both free t-PA and t-PA/PAI-1 complexes to LRP/a2MR. Thus, these findings suggest that LRP/a2MR may function as a clearance receptor for t-PA in vivo and that the 39-kD protein may modulate t-PA clearance. In the present study we examined the physiology of the 39-kD protein, including its inhibitory role in t-PA clearance in vivo.
Methods
Reagents. Single-chain recombinant human t-PA expressed in Chinese hamster ovary cells was generously supplied by Genentech (lot 9124AX; South San Francisco, CA). Asialoorosomucoid and orosomucoid were from the American Red Cross. Carrier-free sodium [ '25I ] iodide was purchased from DuPont New England Nuclear (Boston, MA). IODO-GEN was purchased from Pierce Chemical Co (Rockford, IL). Glutathione-agarose, heparin-agarose, reduced glutathione and thrombin were were collected from the tail artery at the indicated times into ice-cold tubes containing heparin. After collection of the 10-min sample, the chest cavity was opened and a second "10-min" sample was obtained by direct cardiac puncture. Thereafter the liver, spleen, and kidneys were removed, blotted, and weighed. 251I-radioactivity was determined in a Packard gamma counter. Each of the heparinized blood samples was centrifuged, and 25 Ml of the plasma fractions were spotted onto 3-mm filter paper (Whatman, Inc., Clifton, NJ), precipitated with 10% TCA, rinsed with ethanol, and 1251I-radioactivity was determined.
In studies of in vivo t-PA enzymatic activity, unlabeled t-PA (30 pmol) was administered intravenously either alone or following preinjection of 250 nmol of unlabeled 39-kD protein. Blood samples were collected at the indicated times as described above. (The 4-min sample was from cardiac puncture.) The resultant plasma was assayed for t-PA enzymatic activity using the solid-phase fibrin-tissue plasminogen activator activity assay (SOFIA-t-PA) ofAngles-Cano (35) as modified by Sobel and colleagues (36) . Briefly, plasma samples were incubated in microtiter wells coated with a fibrin monomer for 2 h at 37°C. (21) . For these studies, we cleaved the GST-39-kD fusion protein with thrombin and assessed the ability of cleaved and purified 39-kD protein to inhibit 125I-t-PA binding to MHC, cells. Our purified preparation of recombinant 39-kD protein is seen in the inset in Fig. 1 . We found that cleaved and purified 39-kD protein is a more potent inhibitor of '25I-t-PA binding to MHC, cells than the GST-39-kD protein. As seen in Fig. 1 , purified 39-kD protein inhibits '251-t-PA binding to MHC, cells in a dose-dependent manner with an apparent Ki of 0.5 nM.
39-kD protein inhibits '251-t-PA clearance in the rat. Fig.  2 A shows the plasma clearance of '251-t-PA following intravenous administration of 30 pmol of 1251-t-PA in the rat. The initial plasma half-life is approximately 1 min with < 10% of the administered dose remaining in the circulation at 10 min. The plasma clearance curve seen in Fig. 2 A is typical of previously reported plasma clearance curves for t-PA in rats in that the rapid phase of clearance has a half-life of about 1 min. (27, 28, 32, 37, 38) . Approximately 90% of the administered dose was found in the liver at 10 min. In order to determine whether t-PA clearance is a specific and saturable process, a 400-fold molar excess of unlabeled t-PA was administered to rats before the 30 pmol of '25I-t-PA. Under these conditions plasma clearance of the '251-t-PA was markedly decreased with a t112 of approximately 9 min, and > 40% of the administered dose remained in the circulation at 10 min. Approximately 70% ofthe injected 1251-t-PA was associated with the liver at 10 min.
Analysis of plasma samples from in vivo clearance studies using SDS-PAGE and autoradiography demonstrated that the vast majority of the '251I-t-PA (> 85%) was present as free enzyme. < 15% of the '251-t-PA was complexed with PAI-I at all time points examined (0-10 min) (data not shown). These results are in agreement with those of Fuchs et al., who also demonstrated that t-PA is cleared from the circulation as free t-PA and not in a complex with PAI-1 (29) .
Clearance experiments were performed in order to determine whether preadministration of purified 39-kD protein to rats would alter 1251I-t-PA clearance. As seen in Fig. 2 nous administration of 250 nmol of purified 39-kD protein prolonged the plasma half-life of '25I-t-PA from 1 min to approximately 5-6 min. Over 30% of the administered 251I-t-PA remained in the blood at 10 min. -80% of the injected '251-t-PA was associated with the liver at 10 min.
Additional plasma clearance studies with well-characterized ligands (e.g., orosomucoid and asialoorosomucoid) were performed as controls. As seen in Fig. 2 B, the parent compound, orosomucoid, is very slowly cleared from the circulation in the rat with a t,12 of 90 min. However, upon removal of the terminal sialic acid residues, the resultant asialoorosomucoid is cleared very rapidly with a t,2 of -30 s. These results are essentially identical to those seen earlier with these ligands (39) .
In order to determine whether administration ofthe 39-kD protein would alter the enzymatic activity of t-PA in vivo, unlabeled t-PA was administered to rats intravenously either alone or following preadministration of purified 39-kD protein. Thereafter plasma samples were assayed for t-PA enzymatic activity as described in Methods. Preliminary studies in vitro demonstrated, using the same molar ratio of t-PA to 39-kD protein used in vivo, that the 39-kD protein did not alter t-PA enzymatic activity (data not shown). Figure 3 . Effect of 39-kD protein on the enzy-* matic activity of t-PA * in rats. As described in * Methods, rats were in-* jected with 30 (Table I ). The remaining fraction of 125I-39-kD protein not found in the liver and kidney at 10 min was still in the circulation (Fig. 4) . There was no change in the fraction of "'I-39-kD protein found in the spleen (1.7-2.5%) under any of these conditions (Table I) . Clearance capacity of the liver and kidney for the 39-kD protein. Receptor-mediated protein clearance systems are well described for several circulating proteins (39) (40) (41) (42) . Receptormediated endocytosis describes a process whereby extracellular proteins are trafficked into the cell and ultimately are released into the extracellular milieu either intact or degraded. This process requires more than 20 min in liver, kidney, and other tissues (43, 44) . Therefore a measure of an organ's capacity to clear a given protein from the circulation can be assessed independently from degradation and/or cellular release by determining the organ distribution of the protein at 10 min. Thus, we assessed the organ distribution ofthe 39-kD protein 10 min after its intravenous administration. As seen in Table I, (Table I ). (Table I ). The remaining 39-kD protein was in the blood (i.e., as seen in Fig. 4 (Fig. 5 B) , consistent with the results seen in Table I . The pattern of radioactivity in the liver (Fig. 5 D) appeared more homogeneous and of substantially less intensity when compared with the liver ofthe rat following l25I-39-kD protein only. Kidney clearance may be via glomerular filtration and/or cellular uptake. Therefore we examined the kidney by microscopic autoradiography 10 min following the 39-kD protein administration. The hematoxylin-and eosin-stained autoradiograms of kidney sections from rats administered with 12511 39-kD protein in the absence or presence of 125 nmol of unlabeled 39-kD protein appeared similar. Figs. 6, A and B show kidney sections from a rat administered with 30 pmol of 125I1 39-kD protein. The majority of grains appeared within Bowman's space (Fig. 6 A) and within the lumen of the proximal tubules (Fig. 6 B) . Only a minor fraction of the grains were cellular. Cortical glomeruli contained more grains than juxtamedullary glomeruli (data not shown).
Liver sections were also examined by autoradiography ( Fig.  6 Cand D). The grains in the liver sections ofrats that received only '25I-39-kD protein (Fig. 6 C) were predominantly cellular. However, in rats that received 125 nmol of unlabeled 39-kD protein before the '25I-39-kD protein (Fig. 6 D) the vast majority of grains were within the sinusoidal lumen. Discussion t-PA is a serine protease that catalyzes the initial and rate limiting step in the fibrinolytic cascade by converting the zymogen plasminogen to plasmin. t-PA is used widely as a fibrinolytic agent in the treatment of acute myocardial infarction (23) . One substantial limitation to the clinical use oft-PA is its rapid plasma clearance (half-life is -1-5 min), which is predominantly due to an active uptake system in the liver (24) (25) (26) (27) (28) (29) (30) (31) . Recent studies using both human and rat hepatoma cells have demonstrated that LRP/a2MR is an hepatic clearance receptor for both free t-PA (21 ) and t-PA/PAI-l complexes (22) . The 39-kD protein is a potent inhibitor of all known ligand interactions with LRP/a2MR, including t-PA and t-PA/PAI-l complexes, as shown by both ligand binding and by ligand uptake experiments in cultured cells ( 1, 2, 6, 15, 21, 22) . Because the 39-kD protein inhibits '251I-t-PA binding to the t-PA receptor in rat hepatoma MH1CI cells, we administered this protein to rats just before injecting '23I-t-PA and found that the 39-kD protein prolonged the half-life of t-PA five-to sixfold. We also found that the plasma half-life oft-PA enzymatic activity was similarly prolonged following intravenous administration of the 39-kD protein. These found that the 39-kD protein specifically binds to and is endocytosed by hepatic MH1C, cells (S. P. Iodonato, G. Bu, E. A.
Maksymovitch, and A. L. Schwartz, submitted for publication). These results therefore suggested that the 39-kD protein may be cleared in vivo. Indeed, as seen in Fig. 4 (23) (24) (25) (26) (27) (28) (29) (30) , the tissue distribution of '251-t-PA radioactivity seen in the present study indicates that the majority of t-PA is cleared by the liver. Although LRP/ a2MR is expressed in many different tissues (46) , its endocytic function appears to be expressed predominantly in the liver. When injected into the circulation, specific ligands for LRP/ a2MR are predominantly cleared by the liver (47), which is also the major site of t-PA clearance. We propose that LRP/ a2MR functions in vivo as a clearance receptor for t-PA. We recently found that antibodies generated against LRP/a2MR could inhibit t-PA binding to hepatic cells (22) . Whether antibodies to LRP/Ca2MR alter t-PA clearance in vivo remains to be established.
The tissue distribution of '251-39-kD radioactivity suggests there are two sites ofclearance for the 39-kD protein, one residing in the liver and another in the kidney. Since the 39-kD protein binds to LRP/a2MR with high affinity (2), we propose that LRP/a2MR functions as a high affinity clearance receptor for the 39- ( 16) and that binds the 39-kD protein with high affinity ( 12) . gp330 has been localized, via immunoelectron microscopy, to clathrin-coated pits both in the proximal tubule brush border and in the glomerular epithelium ( 19, 48, 49) . The localization of gp330 to clathrin-coated pits of the tubule epithelial cells suggests that gp330, like LRP/a2MR, may be involved in the endocytic internalization of ligands. Since the sites of 39-kD protein clearance and gp330 localization coincide, gp330 may well play a role in 39-kD protein clearance in the kidney. Further studies of the physiology of 39-kD protein interaction in the kidney in vivo will be necessary to further resolve this issue.
Our findings thus demonstrate that recombinant 39-kD protein, when injected into rats, can markedly decrease t-PA clearance and prolong t-PA enzymatic activity via inhibition of the hepatic t-PA receptor, LRP/a2MR. In addition, we have demonstrated that this regulatory ligand, the 39-kD protein, is rapidly cleared from the circulation and is taken up by both the liver and kidney.
